Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 217

The DOI matches its Crossref record.

Topical butyrate improves efficacy of 5‐ASA in refractory distal ulcerative colitis: results of a multicentre trial

Vernia, P., Annese, V., Bresci, G., D’Albasio, G., D’Incà, R., Giaccari, S., Ingrosso, M., Mansi, C., Riegler, G., Valpiani, D., Caprilli, R., GISC (Gruppo Italiano per lo Studio del Colon and del Retto) · 2003 · European Journal of Clinical Investigation

Abstract

Background The treatment of distal ulcerative colitis, refractory to conventional 5‐ASA/steroid treatment, is still a matter of debate. The present study aimed at confirming, with adequate statistical power, previous data indicating the usefulness of topical butyrate and 5‐ASA in the treatment of this condition. Design Double‐blind, placebo‐controlled, multicentre study. A total of 51 patients with distal (< 65 cm) ulcerative colitis, refractory to topical 5‐ASA/cortisone, were randomly allocated to receive topical 5‐ASA 2 g and 80 mM L−1 sodium‐butyrate bid (Group A; 24 patients) or 5‐ASA 2 g and 80 mL saline bid (Group B; 27 patients) for 6 weeks. Sigmoidoscopy with biopsies, as well as clinical and laboratory evaluations, were carried out at enrollment and at the end of the trial. Primary endpoints: remission or marked improvement in endoscopic, histologic and clinical findings. Results Most parameters showed a significant improvement vs. baseline in both groups. Remission in six patients and improvement in 12 patients in Group A vs. one remission and 13 with improvement in Group B (P < 0·05). A significant difference in favour of Group A was recorded regarding the number of bowel movements (P < 0·01), urgency (P < 0·05) and the patients’ self evaluation (P < 0·01). Discussion The combined treatment with topical butyrate and 5‐ASA is significantly more effective than 5‐ASA alone in the management of refractory distal colitis. Further improvements in the treatment of refractory distal ulcerative colitis may be feasible based on the identification of patient subgroups and the association of two or more active drugs. Butyrate may well be one of them.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2362.2003.01130.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 217

Metadata

Authors
Vernia, P., Annese, V., Bresci, G., D’Albasio, G., D’Incà, R., Giaccari, S., Ingrosso, M., Mansi, C., Riegler, G., Valpiani, D., Caprilli, R., & del Retto), G. (. I. P. L. S. D. C. A.
Venue
European Journal of Clinical Investigation
Publisher
Wiley
Published
2003-03
Volume
33
Issue
3
Pages
244-248
ISSN
  • 0014-2972 (ISSN-L)
  • 1365-2362
OpenAlex
W2133269995
Cited by
217
References
0
FWCI
5.53
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Topical butyrate improves efficacy of 5‐ASA in refractory distal ulcerative colitis: results of a multicentre trial. https://app.cochat.ai/papers/10.1046/j.1365-2362.2003.01130.x
The paper
Vernia, P., Annese, V., Bresci, G., D’Albasio, G., D’Incà, R., Giaccari, S., Ingrosso, M., Mansi, C., Riegler, G., Valpiani, D., Caprilli, R., & del Retto), G. (. I. P. L. S. D. C. A. (2003). Topical butyrate improves efficacy of 5‐ASA in refractory distal ulcerative colitis: results of a multicentre trial. European Journal of Clinical Investigation. https://doi.org/10.1046/j.1365-2362.2003.01130.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.